TAK-188-1501

About this trial

Last updated 10 days ago

Study ID

TAK-188-1501

Status

Recruiting

Type

Interventional

Phase

Phase 1/Phase 2

Placebo

Accepting

18+ Years

All

Not accepting

Healthy Volunteers

Trial Timing

Started 5 months ago

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing. In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants tolerate the treatment with TAK-188 and to learn if TAK-188 works well in adults with certain advanced cancers after their previous treatments didn't work. Participants may receive TAK-188 for up to 1 year. Their health will be monitored after the treatment has ended for up to another year.

Inclusion Criteria

Men and women can take part.

Must be 18 years or older.

Must have the following types of cancers which have progressed after routine treatment or treatment is not tolerated: stomach-related (esophageal, gastroesophageal, and gastric), cancer of the pancreas, certain non-small cell lung cancers, squamous cell cancer head and neck cancer, cancer of the colon or rectum (colorectal).

Must be able to perform daily activities well (Eastern Cooperative Oncology Group or ECOG performance status of 0 or 1).

Must have good kidney and liver function and blood counts